Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: iStock
A sexually transmitted form of Shigella, a highly contagious bacterium that causes severe diarrhea, is spreading rapidly among gay, bisexual and other men who have sex with men (GBMSM) in the UK, according to a new study published in The Lancet Infectious Diseases.
The study, led by researchers at the University of Cambridge, found that sexually transmitted Shigella strains are spreading faster than non-sexually transmitted strains and evolving resistance to key antibiotics at an alarming rate.
“Many men who have sex with men are unaware of the serious and increasing risk posed by sexually transmitted Shigella,” said Professor Kate Baker, senior author of the study from Cambridge’s Department of Genetics.
“Sexual infection is now a sustained part of Shigella transmission in the UK. It is vital that this message reaches the communities most affected, so we can help to prevent the spread,” Baker said.
“Sexually transmissible shigellosis needs to be treated as a distinct public health threat, requiring different surveillance, prevention, and treatment strategies.”
Using genomic sequencing techniques similar to those used to track COVID-19 variants, researchers mapped how Shigella bacteria spread and evolved across the UK. The study, conducted in collaboration with the UK Health Security Agency (UKHSA), analyzed 3,514 laboratory-confirmed Shigella samples collected across the UK between 2004 and 2020 from people aged 16 years and older.
Sexually transmitted Shigella spread significantly faster than strains acquired through food, travel, or other non-sexual routes.
Over an evolutionary period of about 2.5 years, sexually transmitted strains spread an average of 117 km between related cases, compared with 46 km for non-sexually transmitted strains.
Sexually transmitted Shigella is primarily circulating within GBMSM sexual networks, particularly in major cities including London, Brighton and Manchester.
No statistically significant increase was seen among non-GBMSM populations, and little evidence was found that infections are spreading widely beyond these sexual networks.
More than half of all Shigella infections in the UK are now sexually transmitted.
Around 30% are linked to international travel, while the remaining cases result from localized outbreaks, particularly among young children, and household transmission.
Professor Baker recommended the following steps to reduce the risk of sexually transmitted Shigella:
Researchers found that antibiotic-resistant sexually transmitted Shigella strains are spreading 71% faster than drug-susceptible strains. More than 70% of sexually transmitted Shigella strains were resistant to at least one clinically important antibiotic.
“This isn’t just one form of sexually transmissible diarrhea. This is multiple overlapping variants emerging that are all quickly becoming resistant to the drugs we use to treat them,” said Baker. “It’s highly likely that if you contracted your Shigella through sex you require different treatment to someone who contracted it through travel.”
Researchers also believe the rise in resistance may partly be driven by antibiotics prescribed to treat or prevent other sexually transmitted infections.
“Our evidence suggests that the variants of Shigella transmitting in sexual networks were actually getting resistant against treatments for other STIs, like gonorrhoea, so people need to remember that when they’re taking antibiotics they’re treating their whole body,” said Baker.
Credit: X
The Trump administration recently launched an initiative, encouraging hospitals across the United States to improve the quality of the meals they serve in terms of nutrition.
Launching the voluntary initiative aimed at making healthier meals more accessible to patients, visitors, and healthcare workers, the announcement was made by the U.S. Department of Health and Human Services (HHS).
The initiative, announced by the U.S. Department of Health and Human Services (HHS), is part of Trump administration's “Make Hospital Food Healthier” pledge.
Hospitals that participate commit to offering more nutritious food and beverage options, increasing transparency around nutritional information, and creating food environments that better support long-term health.
Health officials say hospitals should set an example by promoting healthy eating rather than offering meals and snacks that are high in sugar, sodium, and saturated fats.
HHS said while announcing the initiative, “Healthcare facilities should reflect the same evidence-based nutrition principles they encourage patients to follow after they leave the hospital.”
Also read: Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly Insulin
Under the voluntary pledge, participating hospitals are encouraged to:
The administration says these changes will help create healthier food environments while supporting the prevention of chronic diseases like obesity, type 2 diabetes, and cardiovascular disease.
Millions of Americans eat meals in hospitals each year, whether as patients, family members, or healthcare workers. Public health experts have always argued that hospitals should encourage eating habits instead of relying heavily on processed foods and sugar-sweetened beverages.
Improving hospital food can also benefit healthcare staff, who often work long shifts and depend on hospital cafeterias and vending machines for meals.
The initiative supports the idea that nutrition plays a significant role in preventing and managing chronic illnesses, which remain one of the leading causes of death and healthcare spending in the United States.
The HHS pledge is voluntary, meaning hospitals are not required to participate. Instead, the department is encouraging health systems to adopt healthier food standards as part of their commitment to patient care and community health.
Officials say hospitals that join the pledge can help reinforce healthy lifestyle choices beyond clinical treatment by making nutritious foods more readily available throughout their facilities.
While the program does not mandate specific dietary standards, it represents another step in Trump administration's broader effort to promote healthier eating environments within healthcare settings.
As more hospitals sign on, health officials hope the initiative will have a positive impact on how healthcare institutions approach nutrition, turning hospitals into places that support healthy choices both inside and outside the examination room.
Credit: Reuters
Paxlovid, the oral antiviral used to treat COVID-19, appears to be safe and well-tolerated in children aged 6 years and older, according to a new study.
The study, published in the journal Pediatrics, Paxlovid is safe for children who weigh at least 44 pounds who have mild to moderate COVID-19 but are at risk of developing severe disease. The drug did not cause any serious safety concerns.
Paxlovid was approved by the US Food and Drug Administration (FDA) for adults in 2023 and is currently authorized for children 12 years and older who weigh at least 88 pounds (40 kg). The new findings suggest the treatment could also be appropriate for younger children, although the study does not represent a new FDA approval for children aged 6 to 11 years.
The Pfizer-led study enrolled 75 children aged 6 to 17 years, all of whom received at least one dose of Paxlovid. Participants were divided into two dosing groups based on body weight.
Also read: Long COVID Rehab Program May Help Improve Brain Fog, Study Finds
Researchers found that:
The most commonly reported side effects were:
The researchers concluded that the pediatric dosing regimens produced drug exposures similar to adults while maintaining a favorable safety profile.
"Given the continued burden of disease in pediatric patients, even in a post-pandemic era, a convenient outpatient oral treatment option for preventing severe disease in individuals with mild-to-moderate COVID-19 continues to be an unmet medical need," the authors wrote.
Paxlovid is a combination of two medicines:
Clinical trials in adults have shown that Paxlovid remains one of the most effective outpatient treatments for people at high risk of severe COVID-19.
In a pivotal placebo-controlled trial:
Overall, Paxlovid reduced the risk of COVID-19-related hospitalization or death by 86 per cent in high-risk adults.
The FDA first granted Emergency Use Authorization (EUA) for Paxlovid in 2021.
Known side effects include:
The medication can also interact with several commonly used medicines, including statins, making it important for patients to discuss all current medications with their healthcare provider before starting treatment, the FDA said.
© 2024 Bennett, Coleman & Company Limited